Rief Winfried, Kube Tobias
Klinische Psychologie und Psychotherapie, Philipps-Universität Marburg, Gutenbergstraße 18, 35032, Marburg, Deutschland.
Klinische Psychologie und Psychotherapie, Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau, Landau, Deutschland.
Nervenarzt. 2025 Mar;96(2):128-137. doi: 10.1007/s00115-024-01784-5. Epub 2024 Dec 12.
Blinded placebo treatment arms in clinical trials often achieve up to 80% of the clinical improvements of the verum groups. Apparently, the majority of the effects found in the antidepressant groups in clinical trials are due to factors that are not specific to antidepressant treatment. This article reviews the factors that contribute to the high effectiveness of placebo interventions for antidepressants.
A narrative literature review is presented with particular emphasis on placebo effects in antidepressant clinical trials.
There is a particularly strong placebo effect in depression compared to other mental disorders. The magnitude of this effect can be modulated by helpful versus nonhelpful instructions, by patient participation in the decision-making process but also by personal attention, especially if the clinician is perceived as competent and warmhearted. The occurrence of subtle side effects can also reinforce placebo effects. Placebo effects are not only reflected in subjective patient-reported outcome variables but are also evident in neurochemical changes in the body.
Clinicians essentially contribute to the effectiveness of antidepressant treatment through their own behavior. At the same time, the relatively small overall difference between verum and placebo treatments for depression leads to the necessity of a critical evaluation of the cost-benefit ratio, adapted to the individual case. Study designs for the evaluation of antidepressants are required that better reflect the complex interactions between the genuine drug effects and placebo effects.
临床试验中使用盲法安慰剂治疗组往往能达到阳性药物治疗组临床改善效果的80%。显然,临床试验中抗抑郁药治疗组所发现的大部分疗效是由非抗抑郁药治疗特异性的因素所致。本文综述了有助于安慰剂干预对抑郁症产生高效应的因素。
进行叙述性文献综述,特别强调抗抑郁药临床试验中的安慰剂效应。
与其他精神障碍相比,抑郁症中存在特别强烈的安慰剂效应。这种效应的大小可通过有益与无益的指导、患者参与决策过程以及个人关注(尤其是当临床医生被认为有能力且热心时)来调节。轻微副作用的出现也可增强安慰剂效应。安慰剂效应不仅反映在患者报告的主观结局变量中,在身体的神经化学变化中也很明显。
临床医生本质上通过自身行为对抗抑郁治疗的有效性做出贡献。同时,抑郁症阳性药物治疗与安慰剂治疗之间总体差异相对较小,这就需要根据具体情况对成本效益比进行批判性评估。需要设计出能更好反映真实药物效应与安慰剂效应之间复杂相互作用的抗抑郁药评估研究方案。